Back to top
more

Rubius Therapeutics, Inc. (RUBY)

(Delayed Data from NSDQ)

$15.55 USD

15.55
562,642

-0.23 (-1.46%)

Updated May 3, 2019 04:00 PM ET

After-Market: $15.53 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[RUBY]

Reports for Purchase

Showing records 1 - 19 ( 19 total )

Industry: Medical - Biomedical and Genetics

Record: 1

10/14/2022

Company Report

Pages: 4

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 2

05/11/2022

Company Report

Pages: 7

Considerations on Upcoming Milestones Across RUBY?s Pipeline; Reit Buy and Lowering Our PT to $8

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 3

04/11/2022

Company Report

Pages: 7

RTX-240 Data Produces Mixed Signals at AACR But There Is a Path Forward

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 4

02/28/2022

Company Report

Pages: 7

RUBY Ready To Walk The Red Carpet; Reit Buy and $40 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 5

12/17/2021

Daily Note

Pages: 4

From Antigen-Specific Immune Activation to Tolerance: RCTs Can Do It All

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 6

11/09/2021

Company Report

Pages: 7

Earlier-stage Assets Have Key Infection Points in 2022; Reit. Buy and $40 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 7

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for RUBY

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 8

08/10/2021

Company Report

Pages: 7

RTX-240 Continues its Assault on Solid Tumors; Reit Buy and $40PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 9

05/11/2021

Company Report

Pages: 7

Recent RTX-240 Data Giving the Green Light for the RED Platform; Reit Buy and $40 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 10

03/15/2021

Company Report

Pages: 7

RTX-240 Initial Clinical Data Lessens Pipeline Risk; Reit Buy and Raising PT to $40

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 11

11/10/2020

Company Report

Pages: 7

Strong Pipeline Execution Continues; Reit Buy and $28 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 12

10/29/2020

Daily Note

Pages: 4

Our Thoughts on RTX-321 and Red Cell Therapeutics Platform

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 13

08/11/2020

Company Report

Pages: 7

Oncology Pipeline Continues to Advance; Reit Buy and $28 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 14

05/13/2020

Company Report

Pages: 7

Steady Progress With Oncology Pipeline; Reit Buy and $28 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 15

03/13/2020

Company Report

Pages: 7

Thoughts Following Pipeline Reprioritization; Reit Buy and Reducing PT to $28

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 16

11/15/2019

Company Report

Pages: 6

Thoughts Following Delay of First-in-Human Data; Reit Buy and $40 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 17

08/14/2019

Company Report

Pages: 5

First-in-Human Data to Be Readout by Year end as Planned; Reit Buy and $40 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 18

07/11/2019

Daily Note

Pages: 5

Believe RTX-240?s Differentiated Value Propositions Are Underappreciated

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 19

06/26/2019

Company Report

Pages: 85

Initiate With Buy and $40 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 150.00

Research Provided by a Third Party
// eof